Risk-on: FDA setbacks shadow Sarepta’s gene therapy, but valuation screams opportunity
Last Thursday, we came up with the idea to initiate a position in Sarepta Therapeutics. For now, we’re quite underwater in this trade, but we’re far from concerned. Let’s revisit the investment case: What’s going on? Sarepta Therapeutics has come under the scrutiny of the U.S. FDA after two deaths occurred in a clinical trial […]
What is a shelf offering and why does it matter for small cap investors?
As an investor in small caps, you’ll inevitably come across the term shelf offering. A shelf offering is a type of registration document that publicly listed companies in the U.S. can file with the Securities and Exchange Commission (SEC). It gives them the flexibility to issue shares—or other securities—over a period of up to three […]
Q&A: What do you think about PostNL shares?
PostNL’s stock is taking a heavy hit on the market today, losing around 12% of its value and falling to an all-time low of €0.83 per share. The trigger? Kepler Cheuvreux downgraded its rating from Hold to Reduce and lowered its price target from €1.00 to €0.80—pretty much where we are now. We received several […]